Association of genetically enhanced lipoprotein lipase–mediated lipolysis and low-density lipoprotein cholesterol–lowering alleles with risk of coronary disease and type 2 diabetes
<strong>Importance</strong> Pharmacological enhancers of lipoprotein lipase (LPL) are in preclinical or early clinical development for cardiovascular prevention. Studying whether these agents will reduce cardiovascular events or diabetes risk when added to existing lipid-lowering drugs...
मुख्य लेखकों: | Lotta, LA, Stewart, ID, Sharp, SJ, Day, FR, Burgess, S, Luan, J, Bowker, N, Cai, L, Li, C, Wittemans, LBL, Kerrison, ND, Khaw, K-T, McCarthy, MI, O'Rahilly, S, Scott, RA, Savage, DB, Perry, JRB, Langenberg, C, Wareham, NJ |
---|---|
स्वरूप: | Journal article |
प्रकाशित: |
American Medical Association
2018
|
समान संसाधन
-
Association of genetically enhanced lipoprotein lipase-mediated lipolysis and low-density lipoprotein cholesterol-lowering alleles with risk of coronary disease and type 2 diabetes
द्वारा: Lotta, L, और अन्य
प्रकाशित: (2018) -
Association between low-density lipoprotein cholesterol-lowering genetic variants and risk of type 2 diabetes: a meta-analysis
द्वारा: Lotta, L, और अन्य
प्रकाशित: (2016) -
Peningkatan rasio Low Density Lipoprotein Cholesterol dengan High Density Lipoprotein Cholesterol sebagai faktor resiko stroke iskemik
द्वारा: , ARITYAWAN, Fred Septo, और अन्य
प्रकाशित: (2007) -
Genome-wide association study of adipocyte lipolysis in the GENetics of adipocyte lipolysis (GENiAL) cohort
द्वारा: Kulyté, A, और अन्य
प्रकाशित: (2020) -
In vitro and in vivo lipolysis of plasma triglycerides increases the resistance to oxidative modification of low-density lipoproteins.
द्वारा: Skoglund-Andersson, C, और अन्य
प्रकाशित: (2003)